Stockscreener 앱 받기
34.56
5.60%
-2.05
시간 외 거래:
34.00
-0.56
-1.62%
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
UroGen Pharma: An Emerging GARP Stock - Seeking Alpha
UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.com - Investing.com Nigeria
UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.com - Investing.com South Africa
UroGen Pharma Officer Christopher Degnan Files Rule 144 to Sell 2,202 Shares for Tax Withholding - Kalkine Media
To cover equity-award taxes, UroGen Pharma (URGN) officer proposes selling 2,202 shares. - Stock Titan
Form 4 Urogen Pharma Ltd For: 9 October By Investing.com - Investing.com Nigeria
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
UroGen Pharma Ltd. (URGN) stock price, news, quote and history - uk.finance.yahoo.com
UroGen Pharma Ltd. (URGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
UroGen Pharma (URGN) Stock May Still Trade At A Discount To Sales - simplywall.st
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction By Investing.com - Investing.com India
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction - Investing.com
Jefferies reiterates UroGen Pharma stock rating on rival drug data By Investing.com - Investing.com Nigeria
Jefferies reiterates UroGen Pharma stock rating on rival drug data By Investing.com - Investing.com India
UroGen Pharma general counsel sells $64,618 in shares - Investing.com India
UroGen Pharma's General Counsel Reports RSU Vesting and Tax-Related Share Sale - Kalkine Media
UroGen at Wells Fargo conference: launch gains and pipeline widen By Investing.com - Investing.com Canada
UroGen Pharma general counsel sells $64,618 in shares By Investing.com - Investing.com South Africa
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com Canada
UroGen Pharma general counsel sells $64,618 in shares - Investing.com
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com India
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com UK
Tyra Biosciences Shares Tumble 22% as Bladder Cancer Drug Misses Efficacy Benchmark - finance.biggo.com
UroGen Pharma (URGN) GC exercises RSUs, then sells shares for tax withholding - Stock Titan
UroGen Pharma advances with strong Zusduri sales and promising URGN-103 approval ahead - Pluang
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest - Stock Titan
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs - Stock Titan
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares - Investing.com
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com South Africa
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup - ChartMill
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nineteen new employees could receive up to 117,100 UroGen shares over three years. - Stock Titan
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
UroGen Pharma Ltd. (URGN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Trading the Move, Not the Narrative: (URGN) Edition - Stock Traders Daily
UroGen Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
UroGen will speak at three investor events in September - Stock Titan
IntraGel Therapeutics Receives $7M Investment From UroGen Pharma - FinSMEs
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
UroGen Pharma Ltd. (URGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - Sahm
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - simplywall.st
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - Sahm
Urogen Pharma Insider Sold Shares Worth $2,854,853, According to a Recent SEC Filing - Yahoo Finance
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionEarnings Manipulation Risk - careplusvn.com
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - simplywall.st
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionStrong Earnings Momentum - dars.gov.et
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionEarnings Decline Risk - dars.gov.et
1.90%
자본화:
|
볼륨(24시간):